Bristol-Myers Strikes $5M Deal For Orencia
Bristol-Myers Squibb Co. has agreed to pay $5 million plus royalties to settle a patent dispute with Repligen Corp. over the sale of rheumatoid arthritis drug Orencia, Repligen said Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article